Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
- Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate- Follows original $36M Series A raise and brings Series A total to $75M- Proceeds are being used to fund Phase 1b Alzheimer's and DME studies, and bispecific development
SACRAMENTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that it raised $39 million in a Series A extension financing. The extension financing included new investors, Angelini Ventures and Apollo Health Ventures, in addition to existing investors SV Health Investors' Biotech Fund and Dementia Discovery Fund, MRL Ventures Fund, Sanofi Ventures, Eli Lilly and Company, Dolby Family Ventures and Foundation for a Better World. This financing increased Therini Bio's Series A total to $75M.
Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a fibrin/VEGF bispecific.
Therini Bio seeks to target the underlying causes of neurodegeneration. Factors such as aging, genetics and prevalent diseases, such as hypertension and diabetes, lead to vascular dysfunction and the accumulation of toxic fibrin deposits outside of blood vessels. These deposits induce chronic neuroinflammation, resulting in neuronal damage and severe neurogenerative diseases. Therini Bio has developed a novel approach aimed at treating these devastating diseases by specifically targeting the inflammatory epitope on fibrin to halt the destructive effects of neuroinflammation.
THN391, a potential first-in-class, high-affinity humanized monoclonal antibody designed to selectively block fibrin-mediated neuroinflammation without affecting coagulation pathways, demonstrated activity in preventing vascular and neuronal degeneration in preclinical studies of AD and retinal diseases. In a recent Phase 1a trial, THN391 was well-tolerated in healthy volunteers, showed no adverse hematological effects or impact on coagulation and fibrinolysis, lacked an anti-drug antibody response and had dose-proportional pharmacokinetics with a half-life supporting monthly dosing. Supported by the current data and financing, the experienced team at Therini Bio is preparing to begin dosing patients in Phase 1b trials evaluating THN391 in AD and DME.
Tara Nickerson, Ph.D., Chief Executive Officer of Therini Bio and an industry veteran who also played an instrumental role previously in several prominent private and public biotech financings, including as Chief Business Officer of Maze Therapeutics and Prothena Biosciences, remarked, 'We are deeply grateful to partner with such a distinguished investor group, both new and old. Their support enables us to significantly advance our shared vision of delivering patients a rational, innovative approach to potentially treat their debilitating conditions, including Alzheimer's disease and Diabetic Macular Edema. We look forward to advancing the Phase 1b trials to demonstrate the potential benefit of this novel mechanism in patients.'
Thomas Thestrup, Senior Principal at Angelini Ventures, who led the investment on behalf of Angelini Ventures stated, 'We are proud to support Therini Bio's mission to address the underlying vascular and inflammatory drivers of neurodegenerative disease through a truly novel approach. As an active CNS investor, we are excited about Therini's first-in-class selective antibody therapy targeting fibrin-mediated inflammation, offering a groundbreaking path to transform the treatment of diseases such as Alzheimer's and DME.'
About
Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. Therini Bio is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer's disease and Diabetic Macular Edema, where destructive neuroinflammation plays a central role in the disease process. Therini Bio's top-tier syndicate of life sciences investors includes the Alzheimer's Drug Discovery Foundation, Angelini Ventures, Apollo Health Ventures, SV Health Investors' Biotech Fund and Dementia Discovery Fund, Dolby Family Ventures, Dreavent Biotech Investments, Eli Lilly and Company, Foundation for a Better World, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., and Sanofi Ventures. For more information, visit www.therinibio.com.
Contact
Tara Nickerson, Ph.D.Chief Executive Officertnickerson@therinibio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Philip Morris International (NYSE:PM) Declares US$1.35 Dividend; Appoints New U.S. Communications Officer
Philip Morris International recently announced a regular quarterly dividend of $1.35 per share and appointed Jody Sunna as the new U.S. Chief Communications Officer, reflecting the company's ongoing commitment to shareholder returns and strategic leadership. Over the last quarter, Philip Morris' stock price increased by 21%, a significant movement that may have been influenced by these affirmations coupled with the company's strong financial performance. During this period, the market faced volatility due to geopolitical tensions affecting broader indices, yet Philip Morris managed to post a positive return amidst these challenges, supporting the stock's resilience. We've spotted 2 warning signs for Philip Morris International you should be aware of. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent boost in Philip Morris International's shares by 21% in the last quarter may reflect investor confidence, partially driven by the announcement of a US$1.35 dividend per share and key leadership appointments. Over a longer five-year period, the company's total return, including dividends, reached a notable 220.66%. This indicates strong returns for investors. In comparison to the one-year U.S. market return of 11.7%, Philip Morris outperformed significantly. However, when viewed against the U.S. Tobacco industry, which posted a 30.8% return, Philip Morris' performance was also strong but not as high as the industry's. This recent news could potentially impact revenue and earnings projections, especially considering the anticipated hurdles and opportunities linked to its smoke-free products like IQOS and ZYN. These developments underscore the importance of these product segments for future growth. Analysts have set a consensus price target of US$177.15 for the stock, slightly above the current share price of US$175.36. This suggests a moderate discount of around 3.77%. The market expectations reflected in these targets might adjust if Philip Morris continues to leverage its pricing strategy and operational efficiencies successfully. Investors should consider the possible variability due to regulatory and market conditions affecting smoke-free product growth. According our valuation report, there's an indication that Philip Morris International's share price might be on the expensive side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:PM. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Fifth Third Bancorp (NasdaqGS:FITB) Announces Preferred And Common Dividends For Q2 2025
Fifth Third Bancorp announced a series of dividend payments for both preferred and common shares, with preferred stock dividends set for June 30, 2025, and the common stock dividend slated for July 15, 2025. The company's share price moved up 1.78% over the past week, a performance aligned with the broader market trend, which saw a 1.6% climb despite the turbulence caused by geopolitical events. This resilience aligns with strategic developments like the appointment of Marty McAndrew to lead commercial banking in Florida, supporting potential growth even as global markets face challenges. Buy, Hold or Sell Fifth Third Bancorp? View our complete analysis and fair value estimate and you decide. The end of cancer? These 23 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. Fifth Third Bancorp's recent dividend announcements and leadership changes could bolster shareholder confidence, potentially sustaining the company's solid five-year total return of 119.72%. Despite geopolitical challenges, the company's share price gained 1.78% over the past week. It is currently trading at a discount of approximately 14% to analyst price targets, indicating room for market alignment. The company aims to enhance revenue and earnings through loan growth and asset repricing, anticipating record net interest income. These strategies, combined with proactive balance sheet management, highlight a robust approach to sustaining earnings. The news could reinforce analysts' revenue growth forecasts, currently projected at 9.2% annually over the next three years. Over the past year, Fifth Third Bancorp underperformed against the US Banks industry average return of 25.7%. Despite a challenging market environment, the bank's strong capital management, investment in low-cost deposits, and share repurchase plans collectively indicate a commitment to long-term shareholder value enhancement. Take a closer look at Fifth Third Bancorp's potential here in our financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:FITB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
15 hours ago
- Newsweek
Scientists Map How Alzheimer's Begins in the Brain
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. In an unprecedented large-scale study, researchers have mapped out the first molecular events that cause harmful protein buildups in the brain of people with Alzheimer's disease. "By measuring the effects of over 140,000 different versions of proteins, we have created the first comprehensive map of how individual mutations alter the energy landscape of amyloid beta aggregation—a process central to the development of Alzheimer's disease," said paper author and computational biologist Anna Arutyunyan of the Wellcome Sanger Institute in a statement. "Our data-driven model offers the first high-resolution view of the reaction's transition state, opening the door to more targeted strategies for therapeutic intervention," Arutyunyan added. The Alzheimer's Association estimates that some 7.2 million Americans aged 65 and older are presently living with the disease. Its first outward symptom is typically memory problems, but it can lead to delusions, speech issues, disturbed sleep and mood swings. Artist's impression of amyloid-beta peptide buildups within the brain. Artist's impression of amyloid-beta peptide buildups within the brain. selvanegra/iStock / Getty Images Plus At the heart of more than 50 different neurodegenerative diseases is the molecule amyloid beta. This peptide (a chain of amino acids) has a tendency to clump together, forming structures known as amyloid fibrils. In turn, these fibrils gather together into so-called "plaques"—which play a central role in the progression of Alzheimer's disease. The transition from free-flowing amyloid beta to stable fibril structures requires a certain amount of energy—with the peptides having to pass through a "transition state." This state is extremely unlikely to form, accounting for why fibrils and plaques never form in most people. It is also extremely short-lived, which helps account for how difficult it is to study how amyloid beta starts aggregating. Nevertheless, understanding these molecular structures and reactions will be vital for the future development of therapies against Alzheimer's and similar conditions. In the new study, Arutyunyan and colleagues probed the amyloid beta transition by exploring how changing the genetics of the peptide affects its aggregation rate. The team focused on Aβ42, a form of the amyloid beta with 42 amino acids that is commonly found in people with Alzheimer's disease. The researchers used three techniques in their work. First, "massively parallel sequencing" allowed the team to see how changing the amino acids in Aβ42 affects the amount of energy needed to form a fibril. Next, they used genetically engineered yeast cells to measure the rate of the aggregation reaction. Finally, the team used machine learning tools to analyze the results and map out the effect of all the possible mutations of the peptide on fibril formation. In total, the team were able to assess more than 140,000 versions of Aβ42 in one pop—a breakthrough in scale that boosts the accuracy of the resulting models. Read more Map shows states where risk of dementia is highest—are you living in one? Map shows states where risk of dementia is highest—are you living in one? The analysis revealed that only a very few specific interactions between parts of the amyloid beta peptide strongly influenced the rate of fibril formation. Furthermore, the team found that the aggregation reaction begins at one of the tightly packed, water-repellent ends of the peptide, which is known as the C-terminal region. Accordingly, the researchers hope that targeting interactions in this region might allow new means to protect against and treat Alzheimer's disease. "The approach we used in this study opens the door to revealing the structures of other protein transition states, including those implicated in other neurodegenerative diseases," said genomicist professor Ben Lehner, also of the Wellcome Sanger Institute, in a statement. "The scale at which we analyzed the amyloid peptides was unprecedented … we have shown it's a powerful new method to take forward. "We hope this takes us one step closer to developing treatments against Alzheimer's disease and other neurodegenerative conditions," Lehner added. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Alzheimer's disease? Let us know via health@ Reference Arutyunyan, A., Seuma, M., Faure, A. J., Bolognesi, B., & Lehner, B. (2025). Massively parallel genetic perturbation suggests the energetic structure of an amyloid-β transition state. Science Advances, 11 (24).
